Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Therapy-Resistant Depression Clear all
Completed Phase 1 Interventional

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

NCT02911597
View directory record Official record
Conditions
Depression
Interventions
Naltrexone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 18, 2026, 11:56 AM EDT
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NCT03283670
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
Nitrous Oxide 25%, Nitrous Oxide 50%, Placebo Gas
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 18, 2026, 11:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

NCT04239963
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 18, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

NCT01114698
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine XR, Placebo, JNJ26489112
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Arcadia, California • Escondido, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 18, 2026, 11:56 AM EDT
Recruiting Phase 1 Interventional

DBS for Depression

NCT06096207
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Medtronic SenSight Directional DBS lead
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 1 Interventional

Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder

NCT04226352
View directory record Official record
Conditions
MDD, Treatment Resistant Depression, Smoking Cessation, Smoking
Interventions
Dextromethorphan
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

NCT02360280
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
ketamine, midazolam
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AZD6765, Placebo to AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 18, 2026, 11:56 AM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

NCT07127913
View directory record Official record
Conditions
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions
Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 18, 2026, 11:56 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103
View directory record Official record
Conditions
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions
Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo
Device · Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay

NCT01507155
View directory record Official record
Conditions
Treatment Resistant Depression, Generalized Anxiety Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chalfont, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation

NCT04243798
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 18, 2026, 11:56 AM EDT
Withdrawn Phase 4 Interventional

Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment

NCT00178854
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Risperidone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 18, 2026, 11:56 AM EDT
Active, not recruiting Not applicable Interventional

Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S

NCT01984710
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Medtronic Activa PC+S System
Device
Lead sponsor
Emory University
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 18, 2026, 11:56 AM EDT
Completed No phase listed Observational

Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI

NCT05598931
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429
View directory record Official record
Conditions
Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions
SCC DBS
Device
Lead sponsor
Paul Holtzheimer
Other
Eligibility
22 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Exercise to Augment TMS in Those With Treatment Resistant Depression

NCT05913401
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Aerobic Exercise, Video Watching
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Not applicable Interventional Results available

Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression

NCT03953417
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Accelerated intermittent theta-burst treatment
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 2 Interventional

Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes

NCT01527981
View directory record Official record
Conditions
Depression, Type 1 Diabetes
Interventions
Cognitive behavioral therapy for adherence and depression
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 18, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 18, 2026, 11:56 AM EDT